Daré Bioscience, Inc. — Q1 2021 Form 10-Q
Reporting period: Three months ended March 31, 2021. Filed May 13, 2021. Daré is a clinical-stage women’s health biopharmaceutical company with no approved or commercialized products and no revenue to date.
Financial performance and liquidity
| Metric | Q1 2021 | Q1 2020 |
|---|---|---|
| Revenue | $0 | $0 |
| Research and development expense | $5.73 million | $2.38 million |
| General and administrative expense | $1.94 million | $1.86 million |
| Total operating expenses / operating loss | $7.69 million | $4.25 million |
| Net loss | $7.32 million | $4.25 million |
| Basic and diluted loss per share | $0.16 | $0.18 |
| Cash used in operating activities | $8.38 million | $6.60 million |
R&D expense increased $3.35 million year over year, primarily from development of lead candidates (including the Sildenafil Cream Phase 2b trial and Ovaprene and DARE-BV1 work) and Phase 1/Phase 1-ready programs, principally DARE-HRT1. Net loss included a $369,887 gain from forgiveness of the company’s Paycheck Protection Program loan and accrued interest.
At March 31, 2021, cash and cash equivalents were $7.66 million, total current assets $9.60 million, and current liabilities $6.11 million, yielding working capital of approximately $3.49 million. Total assets were $10.52 million and total liabilities $7.26 million. The company had no note payable after PPP forgiveness; it reported $1.0 million of current contingent consideration and approximately $596,000 of operating lease liabilities.
Financing activities provided $11.37 million in Q1, mainly from equity sales. Cash increased $2.99 million to $7.66 million. Common shares outstanding rose from 41.60 million at December 31, 2020 to 47.31 million at March 31, 2021, reflecting equity issuance and warrant exercises. After quarter-end through May 10, the company sold approximately 1.8 million additional shares for about $2.6 million in net proceeds.
Material changes and business developments
- R&D expense increased about 141% year over year; total operating expenses increased $3.44 million. Operating cash use also rose by $1.78 million.
- In March, Daré initiated the Phase 2b RESPOND trial of Sildenafil Cream, 3.6%, for female sexual arousal disorder.
- Daré completed enrollment in the DARE-HRT1 Phase 1 study in March and anticipated topline results in Q2 2021.
- For Ovaprene, the company was preparing an FDA Investigational Device Exemption submission for Q4 2021 and targeted a pivotal study start by Q1 2022.
- The prior ATM agreement terminated April 3, 2021. In April, Daré established a new ATM program permitting up to $50 million in share sales, subject to market conditions and a 3% sales commission.
Outlook, risks, and unusual items
Management planned to prioritize DARE-BV1, Ovaprene, and Sildenafil Cream through the remainder of 2021 and 2022. It expected 2021 R&D expense to increase significantly and potentially exceed twice 2020 R&D expense if programs proceed as planned; R&D spending during the balance of 2021 was expected to exceed Q1. Management estimated the Sildenafil Cream Phase 2b trial would cost approximately $15 million to $17 million in total, not all payable in 2021. G&A expense was expected to increase approximately 10% to 15% in 2021, potentially more if DARE-BV1 commercial-readiness costs arise.
For DARE-BV1, following positive topline Phase 3 results announced in December 2020, Daré planned to submit an NDA by the end of Q2 2021, request priority review, and, assuming submission, priority review, and approval in 2021, anticipated a potential U.S. launch in the first half of 2022. These are targets and depend on FDA decisions and other conditions. The company also targeted Sildenafil Cream Phase 2b topline results by year-end 2021, subject to enrollment and study-size assumptions.
Going concern: The filing states that substantial doubt exists about Daré’s ability to continue as a going concern. Based on its operating plan, the company said it lacked sufficient cash to meet working-capital and liquidity needs for at least the next 12 months from issuance of the financial statements and needed substantial additional capital. Failure to raise funds could force delays, reductions, or termination of programs or cessation of operations. Equity financing may dilute shareholders; debt or partnerships may impose restrictions or require surrender of rights.
Other material risks include clinical-trial enrollment, outcomes and regulatory approval; dependence on third-party manufacturers and service providers; milestone and licensing obligations; and potential COVID-19 effects on trial timelines, costs, and access to capital. The filing reported no material pending legal proceedings and no material change to previously disclosed risk factors. The $1.0 million Microchips contingent consideration liability related to milestones expected to become payable in the first half of 2021; payment could be in cash, shares, or both.
Most important facts for investors to verify
- Whether the company raised enough capital to fund its operating plan, and the resulting dilution from ATM, equity-line, or other share issuances.
- Actual cash runway and operating cash burn compared with the going-concern disclosure and management’s planned clinical spending.
- FDA submission and review status for DARE-BV1, and whether the anticipated approval and launch assumptions remain achievable.
- Enrollment, costs, and reported results for the Sildenafil Cream Phase 2b trial, plus progress toward the Ovaprene pivotal study.
- Whether expected milestone payments, including the $1.0 million Microchips contingent consideration, are triggered and how they are settled.